Synthetic Vaccine Platform Presented At Swine Flu Conference
The synthetic vaccine platform technology of Generex Biotechnology Corp. has been presented at the first International Swine Flu Conference in Washington, DC.
Douglas M. Powell, PhD, director of immunobiology at Antigen Express, a wholly owned subsidiary of Generex, described the advantages of suppressing a pandemic virus by next generation vaccines, such as Generex’s synthetic platform, [...]
DNA Vaccines May Protect Against Pandemic Influenza
Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine discovery, development and delivery, announced preclinical data from two studies of influenza DNA vaccines designed using its SynCon(TM) technology. The data indicated that the consensus H1N1 and H5N1 influenza vaccines achieved significant increases in immune response and provided protection against influenza virus strains not [...]
Pneumococcal Vaccine Program for Developing Countries
The current price of the pneumococcal vaccine is about $70 in US and European countries. The Advanced Market Commitment (AMC) program will provide incentive for pharmaceutical companies to develop vaccines against diseases raging in poor countries by guarantee of fixed price purchase. G8 countries - among them UK, Canada, Italy, Norway and Russia will invest [...]
Vaccine Market Leading Companies and Government Bodies
Leading companies and government bodies in the biodefense vaccines and therapeutics community:
Advanced BioAdjuvants
Aldevron, LLC
AMAR International, Inc.
AVI BioPharma
Battelle
Bavarian Nordic A/S
Bavarian Nordic GmbH
CBMS-JVAP
Center for Biosecurity of UPMC and University of Pittsburgh
Center for Disease Prevention and Control
Chimerix, Inc.
CUBRC
Dalrymple & Associates, LLC
Defense Threat Reduction Agency
Department of Health and Human Services
Department of Homeland Security
DNAvaccine.com
Drinker, Biddle & Reath
DynPort Vaccine Company LLC, [...]
